Ryzodeg 70/30: payments to doctors
Payments that named Ryzodeg 70/30 as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $52K
- Providers
- 14
- Transactions
- 47
- Average per transaction
- $1,105
The per-transaction average — $1,105 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 14 providers the average total is $3,708, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Novo Nordisk | $44,962 | 86.6% |
| Novo Nordisk AS | $6,957 | 13.4% |